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Introduction
Methcathinone (MCAT) is the β -ketone analog of methamphetamine and serves as a parent compound to abused designer drugs that includes mephedrone (4-CH 3 MCAT) and flephedrone (4-F MCAT) (De Felice et al., 2014; Glennon et al., 1987; Spiller et al., 2011) . Like methamphetamine, MCAT functions as a monoamine transporter substrate that selectively promotes release of dopamine (DA) and norepinephrine (NE) over serotonin (5-HT) (Baumann et al., 2012; Cozzi et al., 2013 Cozzi et al., , 1999 . Consistent with MCAT's Schedule I controlled substance classification in the United States, MCAT increases striatal and nucleus accumbens (NAc) DA levels as measured by in vivo microdialysis in rats (Gygi et al., 1997; Cozzi, 2013) . Furthermore, MCAT functions as a reinforcer in nonhuman primate drug self-administration procedures (Kaminski and Griffiths, 1994) and produces an abuse-related facilitation of intracranial selfstimulation (ICSS) in rats . Overall, the preclinical neurochemical and behavioral effects of MCAT are consistent with its accepted abuse liability in humans.
Results from our laboratory and others suggest that the identity of the para (or 4-position) substituent on the MCAT scaffold is a significant determinant of the abuse-related neurochemical and behavioral effects of synthetic MCAT analogs ( Figure 1 ). In particular, the volume of the para substituent on the MCAT scaffold appears to influence its interaction with DA and 5-HT transporters (DAT and SERT, respectively), such that DAT prefers small-volume substituents (e.g. MCAT itself, with a hydrogen atom at the para position), whereas SERT prefers substituents with larger volumes (e.g. mephedrone, with a methyl substituent at the para position) Sakloth et al., 2015) . This shift in preference from DAT to SERT with increasing volume of the para-substituent is evident from in vitro studies of DAT-and SERT-mediated monoamine release in rat-brain synaptosomes, and this in vitro measure of This article has not been copyedited and formatted. The final version may differ from this version. (Bauer et al., 2013; Bonano et al., 2015) . For example, mephedrone (4-CH 3 MCAT) has lower selectivity than MCAT to promote DAT-vs.-SERTmediated monoamine release in rat-brain synaptosomes and produces weaker ICSS facilitation than MCAT (Bonano et al., 2014) .
The correlation of ICSS effects of para-substituted MCAT analogs (and other monoamine releasers) with in vitro DAT-vs.-SERT selectivity suggests that these behavioral effects might also correlate with in vivo selectivity to promote DA vs. 5-HT release. For example, it is well established that increased DA release in NAc plays a key role in mediating abuse-related effects of many classes of abused drugs (Di Chiara and Imperato, 1988) .
Conversely, drug-induced increases in 5-HT levels appear to oppose and limit DA-mediated effects that contribute to abuse (Czoty et al., 2002; Navailles et al., 2008; Baumann et al., 2011) .
The goal of the present study was to further evaluate the relationship between in vivo selectivity to increase NAc DA vs. 5-HT levels and both (a) in vitro measures of DAT-vs.-SERT selectivity and (b) expression of abuse-related behavioral effects. Toward this end, this study used an in vivo microdialysis procedure to determine the potency and time course of effects produced by MCAT and five para-substituted MCAT analogs on NAc DA and 5-HT levels in rats. We hypothesized that the selectivity, and not absolute DA or 5-HT changes, of these drugs to increase NAc DA vs. 5-HT levels would correlate with our previously determined measures of both in vitro DAT-vs.-SERT selectivity (using a rat brain synaptosome procedure) and in vivo expression of ICSS facilitation Sakloth et al., 2015) . Moreover, we also hypothesized that in vivo selectivity to increase DA vs. 5-HT levels would also correlate with the volume of the para substituent on the MCAT scaffold. 
Drugs
This study determined the neurochemical effects of MCAT and five para-substituted MCAT analogs. For MCAT, the para substituent (the 4-position on the benzene ring of the MCAT scaffold) is hydrogen (H). For the purposes of this manuscript, and for consistency with our previous studies Sakloth et al., 2015) , MCAT analogs are designated using the nomenclature "4-R MCAT," with "R" being the substituent at the para position (see Figure 1 ). In some cases, these compounds also have generic names or other chemical names, and in these cases, alternative names are also listed below. Specifically, the following compounds were studied: MCAT (PubChem CID: 7 216281). MCAT and MCAT analogs were synthesized as their racemic HCl salts using previously described methods . S(+)-Amphetamine hemisulfate (PubChem CID: 3007) and (±)-fenfluramine HCl (PubChem CID: 3337) (Sigma Aldrich, St. Louis, MO)
were tested as comparator phenethylamine controls with selectivity for DAT and SERT, respectively (Baumann et al., 2000) . All compounds were dissolved in sterile saline for intraperitoneal (i.p.) injection, and all drug doses are expressed as the salt forms listed above.
Microdialysis
Surgery
Rats (n=63) were anesthetized with 3.0% isoflurane in oxygen until unresponsive to toepinch and secured in a stereotaxic apparatus (Kopf Instruments, Tujunga, CA, USA). Guide cannulae (8 mm long, 0.5 mm outer diameter; CXG-8, Eicom, San Diego, CA, USA) were implanted bilaterally and terminated 1 mm above the NAc (coordinates: 1.5 mm anterior to bregma, 1.8 mm lateral to midsagittal suture, 6.0 mm ventral to dura). The guide cannulae were secured to the skull using screws (Plastics One, Inc., Roanoke, VA, USA) and orthodontic resin (Butler Schein, Dublin, OH, USA). A dummy cannula (CXD-8, Eicom) was inserted into each guide cannula to maintain cannula patency. Animals were allowed at least 7 recovery days prior to initiating microdialysis testing.
Procedure
On test days, rats were briefly anesthetized with 3.0% isoflurane in oxygen, one of the dummy cannula was removed, and a microdialysis probe (10 mm long, CX-I-8-2, Eicom) with a 2 mm artificial cellulose "cuprophan" membrane (50 kDa molecular weight cut-off) at its tip was inserted into an 8 mm guide cannula such that it extended 2 mm beyond the end of the guide Dialysate samples were collected into a 50 μL injector loop at 10-min intervals using an online auto-injector (EAS-20s, Eicom) and immediately analyzed for DA and 5-HT concentrations by high-pressure liquid chromatography (HPLC) coupled to electrochemical detection (HTEC-500, Eicom). DA and 5-HT were separated using a C 18 -reverse phase column (PP-ODS II, Eicom) and were detected using a graphite working electrode and an Ag + vs. AgCl reference electrode with an applied potential of +450 mV. Preliminary experiments conducted by probe immersion into a known standard concentration of DA indicated a lag time of ~20 min for dialysate to traverse the tubing from the probe to the electrochemical detector at the 1 μL/min flow rate. DA and 5-HT were identified according to characteristic retention times of the standard solution and concentrations were quantified by comparison with peak heights of the standard concentration curve (0.1-100 pg per 10 μL) generated prior to drug administration in each microdialysis experiment. The lower limit of neurotransmitter detection was 0.1 pg. DA and 5-HT levels were determined to be stable after 6 consecutive stable baseline samples were obtained with <25% variability around the running mean of both neurotransmitters.
Testing was conducted using drug doses based on previous behavioral studies from our laboratory (Bauer et al., 2013; Bonano et al., 2015; Bonano et al., 2014) . Specifically, saline at least one week between re-accessing a given site), and each site was used to test a different experimental treatment. At the completion of all experiments, rats were euthanized with CO 2 , and brains were removed and stored in 10% formalin. Probe placement was verified by visual inspection of cannula tracks in unstained brain sections as described previously (Bert et al., 2004; Miller et al., 2015) . Only rats with correct probe placements were included in data analyses (data from n=9 rats were discarded due to improper cannula placement).
Data Analysis
The primary dependent variables were extracellular DA and 5-HT concentrations in each dialysate fraction expressed as a percent of the average of the 6 mean baseline concentrations before drug or vehicle administration for each experiment. The individual normalized DA and 5-HT concentrations were then averaged across rats to yield group mean results for graphical presentation. Results were analyzed for each drug dose using a repeated measures one-way analysis of variance with time as a fixed effect and subject as a random effect (JMP Pro 11, SAS, Cary, NC). Using this analytical method, within-subject comparisons using the Dunnet post-hoc test were determined between monoamine concentrations at each time point and the 10-min "control" monoamine concentration. This 10-min time point represents a dialysis sample that was collected before drug administration, that had advanced into the cannula-to-injector-loop tubing at the time of drug administration, and that reached the working electrode for analysis This article has not been copyedited and formatted. The final version may differ from this version. 
Correlational Analysis
Correlational analyses were conducted to compare selectivities of MCAT analogs to promote in vivo DA vs. 5-HT release in the present study with their selectivities to promote DAT-vs. SERT-mediated monoamine release in previous in vitro studies in rat brain synaptosomes . For each drug in the present study, the maximum increase in mean DA and in mean 5-HT was plotted as a function of drug dose, and log-linear regression was used to determine the drug dose producing a 250% increase in DA and 5-HT levels (ED 250 ).
In vivo neurochemical selectivity was defined as ED 250 for 5-HT ÷ ED 250 for DA (i.e. higher numbers indicate higher potency to increase DA vs. 5-HT and correspondingly higher DA-vs.-5-HT selectivity), and this measure of in vivo neurochemical selectivity was compared to our previous measures of in vitro neurochemical selectivity using a Pearson correlation test.
The measure of in vivo neurochemical selectivity determined in this study was also correlated to two other measures for these compounds described in our previous studies Sakloth et al., 2015) . First, we found previously that in vitro selectivity of 4-R MCAT analogs to promote monoamine release mediated by DAT vs. SERT correlated with a behavioral measure of abuse-related drug effects in ICSS . Accordingly, the measure of in vivo neurochemical selectivity obtained in the present study was also correlated with these previously reported measures of maximal abuse-related ICSS effects. Second, we also reported that a structural predictor of neurochemical and behavioral effects of 4-R MCAT analogs was the volume of the para substituent in the MCAT scaffold . Accordingly, the measure of in vivo neurochemical selectivity obtained in the present study was correlated with the volume of the para substituent . Correlations and statistical analyses were carried out using Prism 6.0 for Mac (GraphPad Scientific, San Diego, CA, USA), and correlations were considered statistically significant if p<0.05. Effects of MCAT and its para-substituted analogs on NAc DA and 5-HT levels MCAT and its five para-substituted analogs produced significant increases in NAc DA and/or 5-HT levels (Figures 3 and 4) . however data for these two rats are included for graphical display. Correlational Analyses Figure 5 shows the maximal % baseline increase in DA and 5-HT levels for MCAT and its 5 analogs. 4-Cl MCAT (10 mg/kg) produced the largest increase (1260%) in DA levels whereas 4-OCH 3 MCAT (32 mg/kg) produced the largest increase (2428%) in 5-HT levels. The potencies and selectivities of each drug to increase NAc DA and 5-HT levels are shown in Table   1 . Of all the MCAT series analogs, MCAT was the most potent compound to increase DA levels and the most DA-vs.-5-HT selective releaser. In contrast, 4-OCH 3 MCAT was the least potent compound to significantly alter DA and/or 5-HT levels, and it displayed the lowest selectivity to increase DA vs. 5-HT levels.
Results
Baseline
This article has not been copyedited and formatted. The final version may differ from this version. Figure 6 shows correlations between the present measures of in vivo neurochemical selectivity and previously reported measures of in vitro neurochemical selectivity to promote monoamine release via DAT and SERT in rat brain synaptosomes (r=0.95, p<0.01; Fig. 6A ), and in vivo efficacy to produce abuse-related behavioral effects in an ICSS procedure in rats (r=0.89, p=0.02; Fig. 6B ). In addition, there was a an inverse correlation between in vivo neurochemical selectivity and steric volume of the para-substituent (r=−0.85, p=0.03; Fig. 6C ) , such that para-substituents with smaller volume (i.e. less steric bulk) were more selective to increase NAc DA relative to 5-HT levels.
Discussion
This study used an in vivo microdialysis procedure to compare the effects of MCAT and five para-substituted MCAT analogs on NAc DA and 5-HT levels in rats. There were two main findings. First, all MCAT analogs produced dose-and time-dependent changes in NAc DA and/or 5-HT levels. Second, the selectivity of these compounds to increase NAc DA vs. 5-HT levels correlated with previously determined measures of (1) in vitro expression of DAT vs.
SERT selectivity in a rat-brain synaptosome procedure, (2) in vivo expression of abuse-related behavioral effects using an ICSS procedure in rats, and (3) the volume of the para-substituent on the MCAT scaffold. Results with this set of compounds support the utility of in vitro drug effects on monoamine release in rat brain synaptosomes to predict in vivo drug effects on monoamine release in rat NAc. These results also support the hypotheses that the steric volume of the para- (Rothman et al., 2001) , S(+)-amphetamine produced a selective increase in NAc DA vs. 5-HT levels, whereas fenfluramine produced a selective increase in NAc 5-HT vs. DA levels. These results are consistent with previous microdialysis studies in both rats (Baumann et al., 2000; Kehr et al., 2011) and nonhuman primates (Laruelle et al., 1997; Murnane et al., 2010; Sawyer et al., 2012) , and confirm the sensitivity of this microdialysis procedure to changes in NAc DA and 5-HT levels produced by agents that have been extensively evaluated. Also consistent with a previous MCAT microdialysis study (Cozzi et al., 2013) , MCAT displayed a greater potency to increase NAc DA vs. 5-HT levels. The present study extends these previous findings by examining a longer time course of MCAT-induced DA and 5-HT effects and using an i.p. rather than an i.v.
route of administration. Also consistent with previous microdialysis results, the addition of a para-methyl group, 4-CH 3 MCAT (mephedrone), significantly altered in vivo DA vs. 5-HT selectivity, such that 4-CH 3 MCAT preferentially increased 5-HT vs. DA levels (Kehr et al., 2011; Baumann et al., 2012; Wright et al., 2012) . The present 4-CH 3 MCAT results extended these previous findings by determining neurochemical effects via the i.p. route of administration.
In summary, these MCAT and 4-CH 3 MCAT results provide the empirical framework for interpreting the effects of other para-substituted MCAT analogs and allows for the subsequent correlation with other in vitro neurochemical and in vivo behavioral measures.
The present results extended previous MCAT and 4-CH 3 MCAT findings by determining the in vivo neurochemical effects of 4 other para-substituted MCAT analogs, which to the best of our knowledge, have not been previously reported. Relative to MCAT, the addition of a parahalogen (-F, -Cl, or -Br) produced qualitatively similar neurochemical effects across all 3 substituents by slightly lowering the potency to increase DA levels and raising the potency to This article has not been copyedited and formatted. The final version may differ from this version. increase 5-HT levels. The result of these changes was a net decrease in DA vs. 5-HT selectivity.
Addition of the 4-OCH 3 and largest-volume substituent to the MCAT scaffold (i.e. methedrone) produced a further decrease in potency to increase DA levels. Relative to 4-CH 3 and 4halogenated analogs, 4-OCH 3 MCAT also displayed reduced potency to increase 5-HT levels;
however, the decline in potency to release DA was larger than the decline in potency to release 5-HT, and as a result, overall DA vs. 5-HT selectivity was lower for 4-OCH 3 MCAT than for any other compound examined.
A major goal of the present study was to determine the degree to which in vivo measures of DA vs. 5HT selectivity for these MCAT analogs might correlate with in vitro measures of their selectivity to promote monoamine release via DAT and SERT in a rat brain synaptosome preparation and a summary of these correlations is shown in Figure 7 . The high and significant correlation between selectivity measures in these in vitro and in vivo procedures supports the utility of this in vitro procedure to predict in vivo neurochemical results.
Moreover, selectivity of these MCAT analogs in both in vitro and in vivo neurochemical procedures correlates both with (a) the volume of the para substituent on the MCAT scaffold, and (b) the efficacy to produce abuse-related behavioral effects in an ICSS procedure Sakloth et al., 2015) . Given the positive correlation between ICSS facilitation and other preclinical and clinical measures of abuse potential (Negus and Miller, 2014) , the present results provide evidence for a mechanism whereby molecular features of a drug molecule (in this case the steric volume of the para substituent of the MCAT scaffold) can determine neurochemical selectivity to act at DAT and SERT and ultimately influence behavioral measures of abuse potential.
This article has not been copyedited and formatted. The final version may differ from this version. The present results with MCAT analogs also agree with studies that examined parasubstituted analogs of either amphetamine or methamphetamine. For example, both 4-F amphetamine (para-fluroamphetamine, aka PAL-303) and 4-CH 3 amphetamine (paramethylamphetamine, aka PAL-313) were more potent to increase NAc 5-HT vs. DA levels (Baumann et al., 2011) . Furthermore, 4-OCH 3 methamphetamine (paramethoxymethamphetamine; PMMA) had a DA vs. 5-HT selectivity ratio of 0.28 (Matsumoto et al., 2014) , which is consistent with the DA vs. 5-HT selectivity ratio of 0.32 for 4-OCH 3 MCAT in the present study. Unfortunately, only DA levels have been reported for 4-Br amphetamine (Zsilla et al., 1981) and 4-Cl amphetamine (Hiramatsu and Cho, 1990; Johnson et al., 1990) , thus precluding a direct comparison of in vivo selectivities between para-substituted amphetamine or methamphetamine analogs and the present results. Nonetheless, these results suggest that neurochemical and behavioral effects associated with para-substitutions to the MCAT scaffold may also generalize to effects associated with effects of para-substituted analogs of amphetamine and methamphetamine.
In the present study, all compounds were administered i.p. to match the route of administration used in previous behavioral studies with these compounds in an ICSS procedure of abuse-potential assessment (Bauer et al., 2013; Bonano et al., 2014; Bonano et al., 2015) . A striking outcome using this route of administration was that DA effects displayed both a slower onset and longer duration than 5-HT effects, and this dissociation in time course of drug effects on DA and 5-HT may be related to route of administration. For example, intravenous 4-CH 3
MCAT produced coincident peak DA and 5-HT effects within 20 min (Baumann et al., 2011), whereas DA effects were more delayed compared to 5-HT effects after subcutaneous administration (Kehr et al., 2011; Wright et al., 2012) , and DA effects were even more delayed reported in previous studies of amphetamine and other para-halogenated or para-methoxy phenethylamines administered by the i.p. route (Marona-Lewicka et al., 1995; Matsumoto et al., 2014) . The reason for these apparent route-of-administration-dependent differences in DA vs. 5-HT time course effects remains to be elucidated.
The present results also afforded an opportunity to compare potency and time course of monoamine releaser effects in rats on in vivo NAc DA and 5-HT levels (present study) and
previously published behavioral effects in our ICSS procedure (Bauer et al., 2013; Bonano et al., 2014; Bonano et al., 2015) . The abuse-related facilitation of low ICSS rates by monoamine releasers is thought to be mediated primarily by increases in DA, whereas abuse-limiting depression of high ICSS rates by these compounds is thought to be mediated primarily by increases in 5-HT (Wise, 1998; Negus and Miller, 2014 In conclusion, the in vivo neurochemical effects of MCAT and 5 para-substituted MCAT analogs support the hypothesis that selectivity of monoamine releasers to elevate DA vs. 5-HT levels via the respective monoamine transporters is a significant contributor to the abuse-related behavioral effects of monoamine releasers in ICSS studies. Although potency differences were noted, all six compounds examined produced similar maximal increases in extracellular DA levels. Thus, the in vivo selectivity differences observed in the present study were mostly driven by decreased potency to increase extracellular 5-HT levels. Furthermore, the present results provide an in vivo neurochemical connection with previous in vitro neurochemical and behavioral effects of these compounds (Bauer et al., 2013; Bonano et al., 2015) . Given the purported direct and indirect connections between serotonergic pathways and the mesolimbic dopamine pathway (Alex and Pehek, 2007) , the present results provide further neuropharmacological evidence for the abuse-limiting effects of 5-HT. been previously reported Sakloth et al., 2015) . previously reported Sakloth et al., 2015) .
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